# Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease

> **NCT05817799** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bahria University** · enrollment: 83 (actual)

## Conditions studied

- Hemodialysis Complication

## Interventions

- **DRUG:** L-Carnitine 500Mg thrice daily
- **DRUG:** 1g L-Carnitine IV three times a week

## Key facts

- **NCT ID:** NCT05817799
- **Lead sponsor:** Bahria University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2023-07-02
- **Final completion:** 2023-07-10
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817799, "Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05817799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*